Chemotherapy-Induced Peripheral Neuropathy (CIPN) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Emerging Therapy and TPP Insights

Thelansis's "Chemotherapy-Induced Peripheral Neuropathy (CIPN) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Overview

Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent and often dose-limiting toxicity resulting from neurotoxic antineoplastic agents, most notably taxanes, platinum compounds, and vinca alkaloids. Pathogenesis involves multifaceted damage to the peripheral nervous system, including axonal degeneration, mitochondrial dysfunction, and direct injury to the dorsal root ganglia, which are vulnerable due to high metabolic activity and a permeable blood-nerve barrier. Clinically, CIPN manifests as a symmetric sensory impairment in a glove-and-stocking distribution, characterized by numbness, paresthesia, and burning pain, and may involve a coasting effect where symptoms progress after treatment cessation. Risk is exacerbated by cumulative drug exposure, advanced age, and pre-existing diabetes. As there are no approved preventive agents, symptomatic management relies on the SNRI duloxetine as the frontline evidence-based intervention, while severe symptoms necessitate dose delays or permanent treatment discontinuation.

Key Highlights

• CIPN is a common, dose-limiting toxicity impacting cancer treatment and patient quality of life
• US cancer incidence (proxy population) expected to grow from ~1.74M to ~1.83M (~0.5% CAGR)

Market Overview

• Germany market projected to grow from ~$170M to ~$290M (~5-6% CAGR)
• Growth driven by supportive care demand and unmet need, with no approved preventive therapies

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Tarian Pharma
• Ono Pharmaceutical Co. Ltd
• Akeso
• Qilu Pharmaceutical Co., Ltd.
• VM Therapeutics LLC
• Dogwood Therapeutics Inc.